Welcome to The Catalyst
Change isn't quick. Unless it's when you experience Intravascular Lithotripsy (IVL) for the first time. Stay apprised of our latest news and insights while discovering how a simple and intuitive tool can be The Catalyst to change the way you think about calcium modification.
At Shockwave, we are committed to doing everything we can to narrow the PCI gender inequality gap starting with clinical evidence presented at SCAI 2022 where Coronary IVL demonstrated sustained long term clinical outcomes and excellent safety in both women and men suggesting first line use of Coronary IVL for plaque modification in female patients with calcified lesions.
Topics: Coronary IVL, IVL Case, DISRUPT CAD, Shockwave Breaking News, IVL Technology, Coronary Cases, Coronary Clinical Data, SWAV News, Shockwave C2, Coronary Conferences, Coronary IVL - U.S.
This year has been “chalk” full of good vibrations at Shockwave! We launched our most efficient IVL catheter yet, the faster-pulsing Shockwave M5+, and its effects have been helping patients with calcified PAD across the globe ever since. Our data also got deeper, with the Disrupt CAD III one-year data published in JSCAI, demonstrating Coronary IVL’s excellent safety and effectiveness outcomes at 30 days out to one year. We heard from physicians like Dr. B. Clay Sizemore on using Coronary IVL in a no-surgical-backup hospital, and Dr. Alexandra Lansky regarding gender disparities in cardiovascular disease. To top it all off, Fast Company recognized Shockwave as one of the World’s Most Innovative Companies for 2022. Check out all of this and more in the latest PulsePoint Newsletter!
Topics: Coronary IVL, IVL Case, Peripheral IVL, IVL Technology, Coronary Cases, Peripheral Cases, Shockwave C2, Shockwave M5, Shockwave S4, PulsePoint Newsletter, Coronary IVL - U.S., ShockwaveM5+
In a few weeks, we are headed to a city known for its sunshine and southern hospitality, Atlanta, Georgia, where SCAI 2022 is taking place this year. At the conference, leading calcium experts will share the 1-year results from the Randomized Disrupt PAD III Trial and 1-year sex specific outcomes with Coronary IVL.
Topics: Coronary IVL, IVL Case, Peripheral IVL, Shockwave Breaking News, IVL Technology, DISRUPT PAD, Coronary Cases, Peripheral Cases, PAD Applications - BTK, Peripheral Conferences, SWAV News, Shockwave C2, Coronary Conferences, Shockwave M5, Shockwave S4, PAD Applications - TEVAR, Coronary IVL - U.S., ShockwaveM5+
After two long years, EuroPCR is finally live again! We can’t wait to meet you in Paris and discuss the latest on IVL.
Topics: Coronary IVL, IVL Case, IVL Technology, Coronary Cases, Shockwave C2, Coronary IVL - U.S.
Some of us know the data. Some don’t. The question once you do is where we go from here to bridge the gender inequality gap?
Topics: Coronary IVL, IVL Case, IVL Technology, Coronary Cases, Shockwave C2, Coronary IVL - U.S.
Discover our PCR webinar featuring European calcium experts, Prof Emanuele Barbato, Prof Javier Escaned, Dr Margaret McEntegart, and Prof Flavio Luciano Ribichini discussing about the most recent OCT data analysis from Disrupt CAD Trials.
Topics: Coronary IVL, IVL Case, IVL Technology, Coronary Cases, Shockwave C2, Coronary IVL - U.S.
Prof. Javier Escaned, Hospital Universitario Clínico San Carlos, Madrid, and Prof. James Spratt, St George’s University Hospital NHS Trust, London, discussed with Cardiovascular News their views about the latest data from the pooled analysis of 262 patients enrolled in OCT sub-studies from Disrupt CAD I, II, III, & IV.
Topics: Coronary IVL, IVL Case, IVL Technology, Coronary Cases, Shockwave C2, Coronary IVL - U.S.
Dr. Benjamin Honton, Interventional Cardiologist at Clinique Pasteur, Toulouse, France, together with Dr. Jacques Monsegu, Groupe Hospitalier Mutualiste de Grenoble, France, write about best practices for IVL use in the cath lab based on his 3 years of experience with the technology. In this review you will find IVL technical, scientific and clinical overview, such as lesion selection with focus on concentric and eccentric calcification, analysis of specific clinical indications and some useful tips for crossing and therapy delivery.
Topics: Coronary IVL, IVL Case, IVL Technology, Coronary Cases, Shockwave C2, Coronary IVL - U.S.
Disrupt CAD Pooled Gender Analysis is now in published in JSCAI - the new journal of the Society for Cardiovascular Angiography & Interventions. Read the JSCAI publication here: https://www.jscai.org/article/S2772-9303(21)00011-9/fulltext
Topics: Coronary IVL, IVL Case, IVL Technology, Coronary Cases, Shockwave C2, Coronary IVL - U.S.
The one-year Disrupt CAD III data has been published in JSCAI – the new journal of the Society for Cardiovascular Angiography & Interventions. The new data from Disrupt CAD III confirm the consistency of the excellent safety and effectiveness outcomes at 30 days out to one year.
Topics: Coronary IVL, IVL Case, IVL Technology, Coronary Cases, Shockwave C2, Coronary IVL - U.S.
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
